Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 21;25(5):2529.
doi: 10.3390/ijms25052529.

Glioblastoma Therapy: Past, Present and Future

Elena Obrador  1   2 , Paz Moreno-Murciano  1 , María Oriol-Caballo  1   2 , Rafael López-Blanch  1   2 , Begoña Pineda  2 , Julia Lara Gutiérrez-Arroyo  3 , Alba Loras  3 , Luis G Gonzalez-Bonet  4 , Conrado Martinez-Cadenas  3 , José M Estrela  1   2   5 , María Ángeles Marqués-Torrejón  3
Affiliations
Review

Glioblastoma Therapy: Past, Present and Future

Elena Obrador et al. Int J Mol Sci. .

Abstract

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians and researchers, no significant improvement in survival has been achieved since the Stupp protocol became the standard of care (SOC) in 2005. Despite multimodality treatments, recurrence is almost universal with survival rates under 2 years after diagnosis. Here, we discuss the recent progress in our understanding of GB pathophysiology, in particular, the importance of glioma stem cells (GSCs), the tumor microenvironment conditions, and epigenetic mechanisms involved in GB growth, aggressiveness and recurrence. The discussion on therapeutic strategies first covers the SOC treatment and targeted therapies that have been shown to interfere with different signaling pathways (pRB/CDK4/RB1/P16ink4, TP53/MDM2/P14arf, PI3k/Akt-PTEN, RAS/RAF/MEK, PARP) involved in GB tumorigenesis, pathophysiology, and treatment resistance acquisition. Below, we analyze several immunotherapeutic approaches (i.e., checkpoint inhibitors, vaccines, CAR-modified NK or T cells, oncolytic virotherapy) that have been used in an attempt to enhance the immune response against GB, and thereby avoid recidivism or increase survival of GB patients. Finally, we present treatment attempts made using nanotherapies (nanometric structures having active anti-GB agents such as antibodies, chemotherapeutic/anti-angiogenic drugs or sensitizers, radionuclides, and molecules that target GB cellular receptors or open the blood-brain barrier) and non-ionizing energies (laser interstitial thermal therapy, high/low intensity focused ultrasounds, photodynamic/sonodynamic therapies and electroporation). The aim of this review is to discuss the advances and limitations of the current therapies and to present novel approaches that are under development or following clinical trials.

Keywords: glioblastoma; immunotherapy; nanotherapy; non-ionizing radiation; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Authors Elena Obrador, Paz Moreno-Murciano, María Oriol-Caballo, Rafael López-Blanch and José M. Estrela were employed by Scientia BioTech S.L. The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
WHO diagnostic criteria for glioblastoma.
Figure 2
Figure 2
Origin of glioblastoma. During normal embryonic development and in the adult brain, neural stem cells (NSCs) generate glial and neuronal cells. Glioma stem cells (GSCs) arise from NSCs, astrocytes, oligodendrocytes, or glial precursor cells through the activation of oncogenic pathways (inactivation of TP53, NF1 or PTEN). GSCs are described as slow-dividing or quiescent cells, with multilineage differentiation capacity that allows them to differentiate into GB cells and cells with astrocytic, neuronal, and endothelial features and even trans-differentiation abilities. In GB tumors, there exists a dynamic equilibrium between quiescent and proliferative GSCs, and between GSC populations and their lineage-committed counterparts (differentiated non-GSC) that can also dedifferentiate into stem-lineage GSCs. Created with BioRender.com, accessed on 24 January 2024.
Figure 3
Figure 3
PTEN/PI3K/Akt/mTOR and RAS/RAF/MEK/ERK axis, and list of related chemotherapeutics clinically assayed against glioblastoma. Created with BioRender.com.
Figure 4
Figure 4
Viruses modified to infect only GB cells or to specifically induce cancer cell elimination can be delivered either directly into brain tumors or intravenously. Created with BioRender.com. Accessed on 15 January 2024.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary. Neuro-Oncology. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
    1. Berger T.R., Wen P.Y., Lang-Orsini M., Chukwueke U.N. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review. JAMA Oncol. 2022;8:1493–1501. doi: 10.1001/jamaoncol.2022.2844. - DOI - PubMed
    1. Kurokawa R., Kurokawa M., Baba A., Ota Y., Pinarbasi E., Camelo-Piragua S., Capizzano A.A., Liao E., Srinivasan A., Moritani T. Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors. RadioGraphics. 2022;42:1474–1493. doi: 10.1148/rg.210236. - DOI - PubMed
    1. Torp S.H., Solheim O., Skjulsvik A.J. The WHO 2021 Classification of Central Nervous System Tumours: A Practical Update on What Neurosurgeons Need to Know—A Minireview. Acta Neurochir. 2022;164:2453–2464. doi: 10.1007/s00701-022-05301-y. - DOI - PMC - PubMed
    1. Thomas D.L. 2021 Updates to the World Health Organization Classification of Adult-Type and Pediatric-Type Diffuse Gliomas: A Clinical Practice Review. Chin. Clin. Oncol. 2023;12:7. doi: 10.21037/cco-22-120. - DOI - PubMed

Substances